|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM32163716X |
| 003 |
DE-627 |
| 005 |
20240725232343.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202007798
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1481.xml
|
| 035 |
|
|
|a (DE-627)NLM32163716X
|
| 035 |
|
|
|a (NLM)33604928
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ji, Qijian
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Targeted Dual Small Interfering Ribonucleic Acid Delivery via Non-Viral Polymeric Vectors for Pulmonary Fibrosis Therapy
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.07.2024
|
| 500 |
|
|
|a Date Revised 24.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Inhibiting the myofibroblast differentiation of lung-resident mesenchymal stem cells (LR-MSCs) is a promising yet challenging approach for pulmonary fibrosis (PF) therapy. Here, micelles formed by a graft copolymer of multiple PEGs modified branched polyethylenimine are used for delivering runt-related transcription factor-1 (RUNX1) small interfering RNA (siRNA) (siRUNX1) to the lung, aiming to inhibit the myofibroblast differentiation of LR-MSCs. LR-MSC targeting is achieved by functionalizing the micelle surface with an anti-stem-cell antigen-1 antibody fragment (Fab'). Consequently, therapeutic benefits are obtained by successful suppression of myofibroblast differentiation of LR-MSCs in bleomycin-induced PF model mice treated with siRUNX1-loaded micelles. Furthermore, an excellent synergistic effect of PF therapy is achieved for this micelle system loaded siRUNX1 and glioma-associated oncogene homolog-1 (Gli1) small interfering RNA (siGli1), a traditional anti-PF siRNA of glioma-associated oncogene homolog-1. Hence, this work not only provides RUNX1 as a novel PF therapeutic target, but also as a promising dual siRNA-loaded nanocarrier system for the therapy of PF
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a lung-resident mesenchymal stem cells
|
| 650 |
|
4 |
|a micelles
|
| 650 |
|
4 |
|a pulmonary fibrosis
|
| 650 |
|
4 |
|a runt-related transcription factor 1
|
| 650 |
|
4 |
|a small interfering ribonucleic acid
|
| 650 |
|
7 |
|a RNA, Small Interfering
|2 NLM
|
| 650 |
|
7 |
|a Micelles
|2 NLM
|
| 650 |
|
7 |
|a Core Binding Factor Alpha 2 Subunit
|2 NLM
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 650 |
|
7 |
|a Bleomycin
|2 NLM
|
| 650 |
|
7 |
|a 11056-06-7
|2 NLM
|
| 700 |
1 |
|
|a Hou, Jiwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yong, Xueqing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gong, Guangming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Muddassir, Mohd
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Tianyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xie, Jinbing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fan, Wenpei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xiaoyuan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 12 vom: 18. März, Seite e2007798
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:12
|g day:18
|g month:03
|g pages:e2007798
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202007798
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 12
|b 18
|c 03
|h e2007798
|